Fig. 6

Vangl2 deletion suppresses mammary tumor metastasis to the lung. a Representative images of formalin-fixed, paraffin-embedded sections from Vangl2^+/+/NDL and Vangl2^fl/fl/NDL lung tissue following immunodetection of ErbB2 (top panel) and H&E staining (bottom panel). Examples of ErbB2-positive metastatic lung lesions are denoted by black arrowheads, scale bar = 500 µm. b–d Lung lobes (5 lobes per mouse) were evaluated by histology for the occurrence of metastatic lesions for Vangl2^+/+/NDL (n = 20) and Vangl2^fl/fl/NDL (n = 20) tumor-bearing animals. The number of mice bearing metastatic lesions (b), numbers of metastatic lesions (c), and metastatic burden (d) were assessed. e–g Vangl2/NDL primary tumor growth characteristics were assessed for Vangl2^+/+/NDL (n = 20) and Vangl2^fl/fl/NDL (n = 20) tumor-bearing animals, including number of palpable tumors (e), total tumor volume (f), and average tumor volume (g). Significance was determined by Mann–Whitney test and bar graphs represent the mean ± sem of experimental replicates (n)